BTBioCircuit Technologies, Inc.AAxogen, Inc.

Overview

Axogen, Inc. agreed to acquire BioCircuit Technologies, Inc., the developer of NerveTape, for total consideration of $200 million in cash at closing, subject to customary purchase price adjustments. Axogen anticipates funding the purchase price with net proceeds from a public offering of its common stock.

Deal rationale

Axogen expects the acquisition to add a differentiated sutureless nerve repair technology that complements its existing portfolio and, combined with its commercial infrastructure and surgeon relationships, to accelerate adoption and be accretive to revenue growth, adjusted EBITDA margin and adjusted EPS.

Timeline

1. AnnouncedSep 10, 2026

   Deal announced.

   Filing

Valuation and terms

Advisors

Parties